MHC Class I Complex Custom Service

Home
Products

products by category

Recombinant proteins
GMP Grade CytokinesNew Fc receptor proteins FcRn Proteins IgG Fc Proteins (Isotype Control) CGT development solutions New Key raw materials for CGT New Targets of CAR-T cell therapy Solid Tumor CAR Targets New CAR Targets for Hematological Malignancies New New Generation Tools for CAR DetectionStar Staining FDA DMF filed proteins Multi-pass TpsHot Immune checkpoint proteins ADC targets BsAb targets TME pathway targets Cytokine TargetsHot Enzymes Llama IgG Fc fusion protein Interleukin Protein Families Hot Biosimilar drug targets Biomarkers & CD antigens All recombinant proteins

Antibodies
Anti-idiotypic antibody Anti-FMC63 mAb Neutralizing antibodies IgG Isotype Control
Support on research about infectious diseases Hot
Core reagents for infectious disease researchNew SARS-CoV-2 related products Reagents for vaccine development SARS-CoV-2 mutant products SARS-CoV-2 related kits Reagents for diagnostic development
Kits/Beads
Cytokine detection ELISA kits New Pre-coupling magnetic beads Inhibitor Screening Kits ELISA Assay Kits for Quantitative analysis of therapeutic antibodies in serum

Featured products

Pre-labeled proteins
New Generation Tools for CAR DetectionStar Staining Biotinylated protein collection FITC & PE labeled proteins
Full-length multi-pass TpsHot
Multi-pass Tps FLAG Claudin Family Claudin 18.2 GPCRs CD20 proteins
Proteins for Neuroscience
Proteins for Neuroscience New Pre-formed Fibrils (PFFs) New Aneuro | Neural Factors New
Streptavidin (SA) series Products
SA, SA Coated Plates, SA Magnetic Beads New
Isotype Controls
IgG Isotype ControlHot IgG Fc ProteinsHot Serum AlbuminHot

Hot targets
CD19 BCMA CD3 proteins IL-2 and IL-2 receptor proteins Inspiring Target: Interleukin 4 Receptor New IL-6 and IL-6 receptor proteins New VEGF proteins IGF family proteins New IFN family proteins New Chemokine family proteins New CD39/CD73 proteins B7 families TNFSF proteins PD1 proteins TIGIT Siglec-15 proteins Integrin CD24&siglec-10
Cytokines
Growth Factors for Cell Culture New Growth Factors for Stem Cell TherapyNew Cytokines for Organoid CultureNew Promising Therapeutic Targets Hot

Brands
FLAG Star Staining ViruStop Aneuro ComboX ActiveMax GENPower ClinMax Star Ribbon
Services

Innovation Lab
SPR /BLI analytical serviceNew Quality Characterization Analytical Service New Enzyme-Linked Immunosorbent Assay (ELISA) Service New Meso Scale Discovery (MSD) ServiceNew Anti-Idiotypic Antibody Development ServiceNew Pseudovirus Neutralization Assay ServiceNew Custom GMP-grade Protein Services New MHC Class I Complex Custom ServiceNew Recombinant Antibody ServiceNew

Licensing Opportunities
PI3Kδ inhibitor New Capsid Assembly Inhibitors for HBVNew RET high selective inhibitor New A SSRI & Partial 5-HT1A Agonist New Reversible MAOB Inhibitor New sGC stimulator New Anti-B7H3 ADC New XO/URAT1 Dual target inhibitors for HUA New
Supports

How to Order Shipping & Payments Global Distributors Testimonials FAQs Download COA
Applications

The Process of How SARS-CoV-2 Infects the Host Quantitative Analysis of mAb in Serum Evaluation of CAR Expression Claudin18.2-VLP：designed for CAR detection SPR & BLI：Binding activity assay SEC-MALS: Aggregation state and purity
News

News Insights Promotions Exhibitions
Resources

Download Brochures Download E-resources Download COA
ACROBiosystems

About Us Join Us Contact Us Partner with us Quality management system

Background

MHC I (Major histocompatibility complex class I), also known as HLA in humans, is a diverse set of cell surface receptors expressed on all nucleated cells in the body. It plays a crucial role in the adaptive immune system. In vivo, MHC I can bind with antigen peptide fragments of intact proteins. The peptide-MHC complex is recognized by the antigen-specific receptors of T lymphocytes, and upon recognition, activated T cells will contribute to the immune response and does help for clear infection. MHC I-displayed peptidome that allows for highly specific T cell-mediated responses which are vitally important for adaptive immunity. Therefore, research on the deep relationship between peptide-MHC I complex and TCR is increasingly significant for the mechanism investigation and drug development.

To better support MHC-related research, ACROBiosystems relies on their mature protein structure design platform alongside their eukaryotic protein expression technology platform to avoid any prokaryotic refolding process instabilities, incorrect complex conformations, and other issues. Using these platforms, we successfully developed a series of natural MHC complexes with high biological activity in both monomer, tetramer forms with various fluorescent labels available. This includes targets such as NY-ESO-1, WT-1, GP100, GPC, and many others. Furthermore, to meet the diverse needs of our customers, we also offer custom MHC-peptide complex development services using our technology platforms to ensure natural conformation according to your specific needs and applications.

Click to Customize

Service Features

Eukaryotic expression platform for a eukaryotic-based conformation

Professional MHC-peptide complex R&D technology platform

Various types of MHC I and antigens are available

Mature bioactivity verification platform: SPR/ELISA/FACS and more

Co-expression of heterodimer results in a more natural conformation

Monomer/Tetramer forms

FITC/PE/APC/Biotin-labeled are optional

Customized Product List

MHC Allele	Target
HLA-A0101 HLA-A0201 HLA-A0301 HLA-A1101 HLA-A2402 HLA-A3303 HLA-B1501 HLA-B1525 HLA-B3802 HLA-B4601 HLA-B*0702 ……	NY-ESO-1 GP-100 MSLN AFP WT1 MAGE-A1 HPV HBV HIV EBV PRAME ……

Click to Customize

High bioactivity verified by FACS

The activity of PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein was higher than that of other competitor.

2e5 of NY-ESO-1 TCR-HEK293 cells (pool) were stained with PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) tetramer Protein（Fig B）and negative control protein respectively (Fig. A), and competitor-M represented competitor protein (Fig. C). PE signal was used to evaluate the binding activity

Inquiry

High binding affinity verified by SPR

Anti-NY-ESO-1 antibody captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Biotinylated Human HLA-A0201 NY-ESO-1 (SLLMWITQC) Complex Protein (Cat. No. HL1-H82E6) with an affinity constant of 16.9 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Protocol

Anti-NY-ESO-1 antibody captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human HLA-A0201 NY-ESO-1 (SLLMWITQC) Tetramer Protein (Cat. No. HL1-H52E8) with an affinity constant of 1.35 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Protocol

Biotinylated Human HLA-C*07:02:01 & B2M & RYR ,His,Avitag™&Tag Free (Cat. No. HLR-H52W2) immobilized on SA Chip can bind Human KIR2DL3, Fc Tag (Cat. No. KI3-H5258) with an affinity constant of 2.40 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

Biotinylated Human HLA-C*07:02:01 & B2M & RYR ,His,Avitag™&Tag Free (Cat. No. HLR-H52W2) immobilized on SA Chip can bind Human KIR2DL2, Fc Tag (Cat. No. KI2-H5255) with an affinity constant of 1.01 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

High bioactivity verified by ELISA

Immobilized Biotinylated Human HLA-A*02:01 NY-ESO-1 (SLLMWITQC) Complex Protein (Cat. No. HL1-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-NY-ESO-1 Antibody, Human IgG1 with a linear range of 0.1-8 ng/mL (QC tested).

Protocol

Immobilized Biotinylated Human HLA-A*02:01 NY-ESO-1 (SLLMWITQV) Complex Protein (Cat. No. HL1-H82E4) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-NY-ESO-1 Antibody, Human IgG1 with a linear range of 0.2-16 ng/mL (QC tested).

Protocol

Related Products

Learn More about CAR-T Targets

Learn More about Fluorescent-labeled Proteins

Learn More about Anti-FMC63 scFv antibodies

Learn More about CD19 Proteins

References

1.Thomas C, Tampé R. MHC I assembly and peptide editing - chaperones, clients, and molecular plasticity in immunity. Curr Opin Immunol. 2021 Jun;70:48-56. doi: 10.1016/j.coi.2021.02.004. Epub 2021 Mar 6. PMID: 33689959.
2.Becar M, Kasi A. Physiology, MHC Class I. 2021 Sep 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 32310482.